timothy sykes logo

Stock News

89bio Stock Surge: Time to Invest?

Tim SykesAvatar
Written by Timothy Sykes Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs
Updated 9/18/2025, 9:19 am ET 9/18/2025, 9:19 am ET | 5 min 5 min read
89bio Stock Surge: Time to Invest? Thumbnail

89bio Inc.’s stocks have been trading up by 85.52 percent after FDA designations and promising results boosted investor confidence.

  • Bank of America trims 89bio’s price target to $29, maintaining Buy ratings due to promising execution in Q2 and pivotal readouts approaching for FGF21 pegozafermin in MASH and SHTG.

  • 89bio joins upcoming investor conferences, reflecting a positive stance on its journey to develop and market treatments for liver and heart-related diseases.

  • Non-qualified stock options have been offered to new employees as part of Nasdaq listing Rule 5635, marking a vested interest in fostering dedicated talent over four years.

  • 89bio attributes inducement grants as a strategic move to strengthen its workforce, underpinning its endeavor to tackle fibrotic diseases effectively.

Candlestick Chart

Live Update At 09:18:28 EST: On Thursday, September 18, 2025 89bio Inc. stock [NASDAQ: ETNB] is trending up by 85.52%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Financial Overview of 89bio

As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” In the fast-paced world of trading, it’s easy to get swept up by the fear of missing out on the latest opportunity. However, successful traders know that patience and discipline are key. By focusing on sound strategies and ignoring the noise, one can avoid costly mistakes and find even better opportunities with time.

In the business world, the numbers tell a compelling story. For 89bio, the recent earnings report showcases both the determination and challenges faced by the company. Their total assets were noted at approximately $603M as of the recent quarter ending in June, a figure attesting to their tangible resources available for driving future growth. However, 89bio has also encountered hefty expenses, reflected in the total expenses reaching over $115M during the same period. Net income showed a negative trajectory of -$111M, revealing the challenges inherent in pursuing innovative research and development in the pharmaceutical world.

The stock’s price currently rides a wave of volatility. From Sept 4, 2025, it was seen opening at $8.02, peaking at $8.47, and closing at $8.08. Such fluctuations are not unusual when there’s anticipation of important trials and financial backing announcements, keenly tied to market sentiment about the company’s upcoming clinical trials.

When you peer a little closer at the company’s financial ratios, certain figures spring out to analysts’ eyes—they seemingly scream potential. Although hampered by negative returns on assets (-75.9%) and equity (-52.6%), the lower debt-to-equity ratio and impressive current ratio of 15.2 signal astrong liquidity position. To explain briefly, 89bio has sufficient resources to meet its short-term liabilities. Potential investors might find that reassuring, especially when firmer financial foundations are laid amid the ongoing developments within their clinical pipeline.

Examining Market Impact: News Insights

With 89bio’s current activities, clinical advances and financial movements are shaping its stock trajectory profoundly. The anticipated efficacy of its FGF21 analog in upcoming trials offers a beacon of hope for many stakeholders. A staggered glimpse at the broader industry landscape hints at increasing enthusiasm for biopharma firms like 89bio making strides against what some consider stubborn ailments—fibrosis and liver issues. This has undoubtedly piqued the interest of institutional traders, reflected in the favorable ratings from H.C. Wainwright and BofA, both cornerstone players in shaping market views.

In conclusion, the string of trader-focused conferences that the company is gearing for indicates 89bio’s striving for an image of transparency and its commitment accorded to long-haul profitability in the global pharmaceutical realm. Their venture into stock options to coax promising talent also signals preparedness to carry their vision forward, aligning growth strategy with market responsibilities.

The current forecast suggests that 89bio is navigating its way through market waters with a healthy confluence of cautious optimism and vigilant strategy. As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.” This sentiment resonates with those contemplating stock engagement, as such cues may either urge cautious exploration or forge confident strides into active participation. With their strategic advancements, 89bio seems set to weave its narrative through the hurts and hopes of the healthcare matrix.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Tim Sykes

Head Writer at TimothySykes.com, Lead Mentor at the Trading Challenge
In his 20-plus years of trading, Tim has made $7.9 million. In his 15-plus years of teaching, Tim’s Trading Challenge has produced over 30 millionaire students. His philosophy emphasizes small gains and cutting losses quickly.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”